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Abstract: 1 
Objective: To identify the prevalence and predictors of prescribing potentially inappropriate 2 
medications (PIMs) in a nationwide cohort of community dwellers with dementia requiring 3 
complex care needs. 4 
Methods: A cross-matched data of the International Resident Assessment Instrument-Home 5 
Care (9.1) (interRAI-HC) andwith prescribing data obtained from the Pharmaceutical Claims 6 
Data Mart (Pharms) extract files for older adults (≥65 years) requiring complex care needs was 7 
utilized for this study. The 2015 Beers criteria were applied to identify the prevalence of PIMs 8 
in older adults with dementia. Sociodemographic and clinical predictors of PIMs were analysed 9 
using a logistic regression model. 10 
 Results: The study population consisted of 16,568 individuals who had their first interRAI 11 
assessment from 1st January 2015 to 31st December 2015. The estimated prevalence of 12 
dementia was 13.2% (2,190/16,568). 66.9% (1,465/2,190) of the older adults diagnosed with 13 
dementia were prescribed PIMs, of which anticholinergic medications constituted 59.6% 14 
(873/1,465). Males and individuals who were prescribed a greater number of medications were 15 
more likely to be prescribed PIMs. Individuals over 85 years of age, Māori ethnic group of 16 
individuals, older adults who were being supervised with respect to their activities of daily 17 
living, and individuals who reported good or excellent self reported health, had a lesser 18 
likelihood of being prescribed PIMs.  19 
Conclusion: We found that PIMs are prescribed frequently in older adults with dementia. 20 
Comprehensive geriatric assessments can serve as a potential tool to decrease the occurrence 21 
of PIMs in vulnerable groups with poor functional and cognitive status. 22 
 23 
Key words: Dementia, potentially inappropriate medications, interRAI, prescribing in older 24 
adults 25 
 26 
Key Points:  27 
The 2015 Beers criteria and interRAI assessments were used to determine the prevalence and 28 
predictors of prescribing potentially inappropriate medications (PIMs) in older adults 29 
diagnosed with dementia, and having complex care needs. 30 
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There was a high prevalence of PIMs in older adults with dementia.  Anticholinergic 1 
medications comprised the most commonly prescribed PIMs. Sociodemographic factors 2 
including younger age, male gender, and New Zealand European ethnicity; and clinical factors 3 
like the increased number of medications prescribed, functional status, and self-reported health 4 
influenced the prescription of PIMs in this vulnerable population.  5 
A due consideration of these attributes while prescribing may aid in reducing the prescribing 6 
of PIMs in individuals with dementia. 7 
 8 
 9 
Introduction: 10 
Dementia is one of the principal syndromes linked with disability and dependence among older 11 
adults and is a major challenge to individuals, communities, and societies globally.1 The global 12 
incidence of dementia is expected to rise to 81 million by 2040, primarily due to the progressive 13 
nature of the disorder, which involves worsening of neurocognitive impairment and loss of 14 
basic functions in daily life.2-4 In 2016, the estimated prevalence of dementia in New Zealand 15 
(NZ) was more than 62,000, which is predicted to increase to 170,000 in 2050.5 One in every 16 
four ‘international Resident Assessment Instrument- Home Care’ (interRAI-HC) evaluated 17 
individuals in 2016-17 in NZ were diagnosed with dementia, of which 35% needed extensive 18 
assistance or were completely dependent, and 30% had showed daily episodes of disturbing 19 
behaviours, like wandering or being abusive.6 The interRAI was developed by an international 20 
collaboration of experts and shows good inter-rater reliability. The interRAI assessors who 21 
conduct the assessments are trained in a quality assurance programme conducted by the 22 
Ministry of Health, NZ. A national competency framework supports and promotes the quality 23 
assurance programs for the interRAI assessments.8 The interRAI-HC tool gathers information 24 
on physical, mental, social, and cognitive domains of the health of residents/clients living in 25 
home care settings.8 26 
 27 
Beers et al have defined potentially inappropriate medications (PIMs) as the prescription of 28 
medications, where the risks outweigh clinical benefits, particularly when there is safer or more 29 
effective alternative therapy for the same condition.9 A study conducted in rural community-30 
dwelling older adults in the United States of America (USA), utilizing the Beers criteria has 31 
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found that half of the population of older adults utilized over-the-counter and prescribed 1 
inappropriate medications.10 Prescribing medications for older adults with dementia is 2 
challenging because of the risks associated with cognitive decline, behavioural and 3 
psychological disturbances, prescription of multiple medications, and their associated 4 
costs.12,13 Older adults with dementia also experience a greater sensitivity to the adverse effects 5 
of medications acting on the central nervous system.14,15 Long-term utilization of medications 6 
in older individuals with impaired physical and cognitive function has been associated with 7 
increased risks of hospitalization and mortality.16  8 
The 2015 Beers Criteria is often used as a tool for assessing the appropriateness of prescribing 9 
medications in the geriatric population.17 A systematic review among older adults with 10 
cognitive impairment and dementia reported a varied prevalence of prescription of PIMs of 11 
10.2%–56.4% across Europe, Australia, and the United States; and the Beers criteria were 12 
applied for assessing PIMs in the majority of the studies.18 Another recent literature review 13 
reported that among the five studies conducted in ambulatory home-dwelling patients 14 
diagnosed with dementia that used the Beers criteria, the prevalence of PIMs use ranged from 15 
16.2% to 33%, and PIMs were found to be associated with the gender, ethnicity, number of 16 
medications prescribed, and varied medical conditions.19 An understanding about the 17 
prevalence and determinants of PIMs can help prevent adverse effects, and improve the quality 18 
of prescribing in this vulnerable age-group. To our knowledge, this is the first study conducted 19 
to evaluate the predictors of prescribing PIMs in older adults with dementia receiving 20 
comprehensive geriatric risk assessments. These assessments capture a suite of 21 
sociodemographic and clinical variables that have not been previously investigated. The study 22 
aims to identify the prevalence and associations of prescribing PIMs in a nationwide cohort of 23 
community dwellers with dementia. The overarching objective of the study is to identify the 24 
factors associated with inappropriate prescribing in older adults diagnosed with dementia, 25 
identified by the 2015 version of Beers criteria, by multinomial regression, utilizing the 2015 26 
interRAI dataset.  27 
 28 
 29 
Materials and Methods:  30 
The Human Ethics Committee, University of Otago, NZ has approved the proceedings of the 31 
study (ethical approval number 15/CEN/45/AM02).  32 
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Data source: The international Resident Assessment Instrument-Home Care (9.1) (interRAI-1 
HC) dataset is a comprehensive geriatric risk assessment for community-dwelling older adults 2 
with complex care needs needing publicly funded long-term community services or aged 3 
residential care in NZ.20 In NZ, a standardized interRAI-HC has been implemented for 4 
conducting all community care assessments in older adults requiring publically funded long-5 
term community services or aged residential care.21 Assessors in District Health Boards 6 
throughout NZ utilize this standardised interRAI-HC assessment to assist in defining the level 7 
of support required for the geriatric population.20 Older adults are referred by a health 8 
practitioner to have their health requirements assessed by the trained interRAI-HC assessors. 9 
Assessors visit the individuals at their residence to develop individualized treatment plans 10 
according to a standardized protocol.22 Once the participating individuals consent to the de-11 
identified interRAI-HC data being used for planning and research purposes, the information is 12 
then collated into the electronic interRAI-HC database, maintained by New Zealand’s 13 
Technical Advisory Services (TAS) to provide facts and figures at the provider, regional and 14 
national level.22 The interRAI-HC assessments provide information on 20 domains, including 15 
social demographics, medical ailments, frailty, cognitive and physical function.21 The interRAI 16 
database is linked to various NZ Ministry of Health nationwide collections, including 17 
prescription use (the Pharms database), hospital discharges (National Minimum Dataset), 18 
laboratory collections and mortality data, among others.21  The information on all the 19 
prescription claims funded by PHARMAC (Pharmaceutical management agency) was sourced 20 
from the Pharmaceutical Claims Data Mart (Pharms) extract files 2015, prepared by 21 
community pharmacists, and includes the sociodemographics and medication details of the 22 
individuals.24 The cross-matched 2015 interRAI-Pharms dataset was utilized for the present 23 
study. 24 
 25 
Study population: The eligible study population comprised community dwellers (>65 years 26 
of age) in NZ who have undergone the first interRAI comprehensive geriatric risk assessment 27 
in 2015. The present study had a retrospective design, tracking the prevalence of PIMs and 28 
dementia, and delineating the factors associated with prescription of PIMs in dementia in older 29 
individuals. The personal information of the individuals is de-identified in the dataset.  30 
 31 
PIMs exposure: PIMs were defined according to the list of medications to be avoided in 32 
individuals diagnosed with dementia as per the 2015 Beers criteria25 developed by the 33 
American Geriatrics Society; which comprised the prescription of psychotropics, including 34 
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antipsychotics, medications with anticholinergic properties, benzodiazepines, 1 
nonbenzodiazepines, benzodiazepine receptor agonist hypnotics, and H2 receptor antagonists 2 
(Table 1). We have excluded medications listed under the 2015 Beers criteria which were not 3 
available or not subsidized in NZ (Appendix 1).  4 
 5 
Diagnosis of dementia: Dementia was diagnosed by the Minimum Data Set (MDS) Cognitive 6 
Performance Scale (CPS).26 The CPS is a valid and reliable seven‐point hierarchical scale 7 
derived from the MDS that rates impairment from intact memory to very severe memory loss.27 8 
The CPS collates data on comatose status, short‐term memory, cognitive skills for daily 9 
decision‐making, being understood by others, and self‐performance in eating;, with scores 10 
ranging from 0 (intact memory) to 6 (very severe memory impairment). The CPS has been 11 
shown to be highly correlated with the Mini-Mental State Examination in a number of 12 
validation studies.  13 
 14 
Covariates: The individuals were grouped according to age: 65-74 years, 75-84 years, 85-94 15 
years, and 95 years and above. Based on the literature review of known predictors of 16 
inappropriate prescribing in older adults with and without dementia, explanatory variables that 17 
were tested for their influence on prescribing patterns were: 18 
1. Sociodemographics: Age 30, gender 30 ethnicities 31, marital status 30, living 19 
arrangements 32,33, alcohol intake 34, and smoking history 35. 20 
2. Clinical: Activities of daily living 30,36, self-reported health 30, hospitalization 32,36, and 21 
number of medications.37,38 22 
 23 
Statistical analysis: The potential impact of different explanatory variables on the outcome 24 
variable (PIMs) was analysed using logistic regression models. 25 
Individuals with a diagnosis of dementia were flagged as a binary variable; those with the 26 
diseased condition were coded as 1, the coding for no dementia was 0. Descriptive analysis 27 
was conducted utilizing the IBM SPSS version 24. Logistic regression analysis was performed 28 
using StataCorp® Release 14.2. We utilized the ‘STrengthing the Reporting of Observational 29 
studies in Epidemiology’ (STROBE) guidelines (www.strobe-statement.org) as the research 30 
reporting guiding principle39 (Appendix 2)  31 
 32 
 33 
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Results:  1 
The current analysis is based on data collected from 16,568 Home-Care assessments from 1st 2 
January 2015 to 31st December 2015, who have received at least one prescription medication 3 
funded by PHARMAC. Our observations suggest that the female population comprised 60.1% 4 
(9,964). The mean (SD) age of the population was 82.35 (7.6) years. Individuals of all 5 
ethnicities were included in the study. NZ Europeans and Māori were studied particularly, as 6 
they represent the largest ethnicities in NZ.31 13.2% (2,190) of the study population was 7 
diagnosed with dementia. Dementia was marginally more prevalent in males (14.6%) 8 
compared to females (p=0.001), and among the Māori ethnicity (16.6%). The 9 
sociodemographic characteristics of the study population are depicted in Table 2, which also 10 
displays the associations of PIMs with the corresponding 95% confidence interval (CI) 11 
(p<0.05), after adjustment for confounders, in individuals diagnosed with dementia. Overall, 12 
we observed that 66.9% (1,465/2,190) of the older adults diagnosed with dementia were 13 
prescribed PIMs, of which 59.6% (873/1,465) constituted anticholinergic inappropriate 14 
medications. Overall, 39.9% (873/2,190) of the individuals diagnosed with dementia were 15 
prescribed anticholinergic PIMs (Figure 1).  16 
Sociodemographic predictors: Individuals over 85 years of age were less likely to be 17 
prescribed PIMs, compared to individuals aged 65-74 years (aOR=0.64, CI=0.53, 0.77 for 18 
individuals aged 85-94 years, aOR=0.53, CI=0.38, 0.73 for individuals over 95 years). Males 19 
were more likely to be prescribed PIMs (aOR=1.24, CI=1.09, 1.41) compared to females. The 20 
Māori ethnic group (aOR=0.59, CI=0.47, 0.76) and the other ethnicity groups (aOR=0.68, 21 
CI=0.54, 0.87) were less likely to be prescribed PIMs, compared to the NZ Europeans.  22 
Clinical factors associated with PIMs 23 
Older adults who were prescribed a greater number of medications were more likely to be 24 
prescribed PIMs (aOR=1.15, CI=1.14, 1.16), compared to those prescribed a single medication. 25 
With respect to the activities of daily living, the older adults who were being supervised 26 
(aOR=0.83, CI=0.69, 0.99) were less likely to be prescribed PIMs, compared to individuals 27 
who were independent in their self-performance and capacity. Older adults who reported 28 
excellent (aOR=0.62, CI=0.43, 0.89) and good self-health (aOR=0.65, CI=0.49, 0.85) had a 29 
lesser likelihood to be prescribed PIMs, compared to those who reported poor self-health.  30 
 31 
 32 
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Discussion:  1 
We reported the prevalence of prescription of PIMS and identified the sociodemographic and 2 
clinical variables associated with the prescription of PIMs among community-dwelling older 3 
adults with dementia. 4 
 5 
Several studies investigating PIMs in older individuals have been carried out in NZ that made 6 
use of the Beers criteria, and have focused on community-dwelling or hospitalized older 7 
adults.31,35,40 This study appears to be the first to apply the 2015 Beers criteria to examine the 8 
associations of inappropriate prescribing exclusively in community-dwelling older individuals 9 
with dementia in NZ, who have received a comprehensive geriatric risk assessment. 10 
 11 
The NZ interRAI annual report 2016-176 noted a 1.2 times higher prevalence of dementia in 12 
males, compared to females, findings consistent with those in our study. Likewise, in the 13 
present study, male individuals diagnosed with dementia were more prone to be prescribed 14 
PIMs, compared to females, similar to the findings of a recent study in Finland41 which reported 15 
the male gender as a risk factor for initiation of PIMs in community-dwelling older adults with 16 
Alzheimer’s disease; and the research conducted in Korea which analysed the trends in 17 
prescribing of atypical antipsychotics in geriatric patients with dementia.42 Numerous studies 18 
have reported a higher rate of inappropriate medication use in older women than in men of the 19 
same age-group 43-45, although the clinical relevance of this association remains uncertain.46  20 
 21 
Our study observed a high prevalence of dementia in the Māori group, comparable to that 22 
observed in a study conducted in NZ to assess an indigenous approach for the diagnosis and 23 
management of dementia47, and to the findings of the NZ interRAI annual report 2016-17.6 It 24 
has been observed that the Māori population over the age of 50 have worse health outcomes 25 
and a greater burden of chronic ailments than non-Māori of the same age-group.48 The 26 
prevalence of PIMs (68.4%) in NZ Europeans with dementia exceeded the occurrence in all 27 
other ethnic groups of individuals, identical to other PIMs prevalence studies in the geriatric 28 
age group conducted in NZ.31,40 This could be attributed to NZ Europeans being the 29 
predominant ethnic group in New Zealand, comprising 71.2% of the country’s inhabitants.49  30 
 31 
A higher proportion (72.3%) of relatively younger group (65-75 years) of individuals with 32 
dementia were prescribed PIMs, which reflects the findings of the study performed by Hyttinen 33 
et al to evaluate PIMs prevalence in community-dwelling older adults with and without 34 
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Alzheimer’s Disease41. These findings could potentially be attributed to prescriber awareness 1 
concerning the prescription of PIMs in individuals of the older age group.50 2 
 3 
There was a high prevalence of PIMs (66.9%) in older adults diagnosed with dementia in our 4 
study, comparable to the prevalence (62%) in a study conducted in community-dwelling older 5 
adults in the USA.51 This is a significant finding of our study. Similarly, researchers in 6 
Australia52 reported a prescription of at least one PIM as 56.4% among individuals with 7 
dementia living in residential aged care facilities. A study of six residential care homes in 8 
England46 observed the prevalence of at least 1 PIM prescribed in 46.2% and 40.9% of the 9 
older individuals with dementia, utilizing the STOPP criteria, reviewed at two time-points, 16 10 
weeks apart. A direct international comparison of the prevalence of PIM prescriptions with our 11 
findings is challenging because of the differences between the PIMs lists used, and the 12 
population under study. Holmes et al have developed a tool for assessment of appropriate 13 
medication prescribing in advanced dementia, in which the primary goal is palliation of 14 
symptoms.53 There is a similar need to arrive at a global consensus through research on 15 
appropriate prescribing in older adults presenting with different stages of dementia.  16 
 17 
One of the most significant findings of our research suggest that 59.6% of the PIMs prescribed  18 
belonged to the anticholinergic class of medications; and 39.9% of the population under study 19 
were prescribed anticholinergic medications which were termed inappropriate to prescribe in 20 
older individuals diagnosed with dementia, according to the 2015 Beers criteria.25 Bhattacharya 21 
et al54 reported a prevalence of 43% of anticholinergic medication prescription among elderly 22 
outpatients with dementia. A study by Somers et al55 reported a high anticholinergic burden of 23 
PIMs in residential aged care facilities in Melbourne. A study by Cross et al56 in Australia also 24 
reported a clinically significant anticholinergic burden in older adults attending Memory 25 
Clinics. Anticholinergic agents are specifically associated with negative outcomes in older 26 
adults diagnosed with dementia, such as risk of falls, delirium, worsening of cognitive function, 27 
and increased mortality.54,57 The anticholinergic agents are notorious for their peripheral side 28 
effects, which include dry mouth, constipation, urinary retention, and bowel obstruction; and 29 
the central side effects such as impaired concentration, confusion, attention deficit, and 30 
impairment of memory.54 PIMs with anticholinergic properties may also inhibit the potential 31 
benefits of cholinesterase inhibitors, which is the main pharmacological class, currently 32 
approved for the management of Alzheimer’s disease.58 Several researchers have attested that 33 
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anticholinergics may be associated with an increased risk for the development of sustained 1 
cognitive deficits, which can range from mild cognitive impairment to dementia.59-61 2 
 3 
The results of the logistic regression analysis showed that the likelihood of PIMs increased 4 
with the number of medications prescribed, which is akin to the findings of the research in 5 
older people with dementia in care homes in the United Kingdom (UK),46 the study by 6 
Wucherer et al in community-dwelling primary care patients screened positive for dementia,62 7 
and the research conducted in Sweden using the EU(7)-PIM list to evaluate the prevalence of 8 
PIMs in older people with cognitive impairment.57 A study performed in UK utilizing the 9 
primary care database of anonymised electronic health records from general practice 10 
witnessed that patients over 65 years of age diagnosed with dementia, and taking multiple 11 
medications, were more likely to be prescribed antipsychotics.63 A higher number of 12 
medications being prescribed may indicate multiple comorbidities. Drug interactions and non-13 
adherence are other risk factors that may have adverse consequences among older adults with 14 
dementia, which are linked to a high number of prescribed medications.57  15 
 16 
In our study, individuals who reported poor self-health had an increased likelihood of 17 
developing PIMs, identical to the results of a study conducted in the USA to assess potentially 18 
inappropriate anticholinergic medication use in home-dwelling older adults with dementia.50 19 
The Bronx Aging Study64 revealed that patients with poor or fair ratings of self-perceived 20 
health utilized more prescription medications. Scores on self-perceived health status may be an 21 
appropriate measure of the syndrome. This is supported by the conclusion that subjects 22 
reporting fair and poor ratings on self-perceived health have increased numbers of physician 23 
visits.64 24 
Contrary to the analysis of studies conducted in individuals diagnosed with dementia in 25 
Sweden65 and in eight European countries66, a striking result to emerge from our data is that 26 
the PIMs prevalence was higher in individuals who were functionally independent with respect 27 
to ADL.  28 
 29 
The study found increased use of anticholinergic medicines in dementia. Several studies have 30 
shown that prescription of anticholinergic medicines can adversely impact cognition, physical 31 
function, and can also increase the risk of mortality. Future research will aim at utilizing the 32 
interRAI assessments for reducing anticholinergic medicines, and whether this leads to 33 
11 
 
improved cognitive outcomes.  Further research will be undertaken to develop safer alternatives 1 
to anticholinergic medications in this vulnerable group.  2 
 3 
 4 
Strength of the study: The strength of this study includes the use of a national comprehensive 5 
geriatric assessment, interRAI tool to record social attributes, clinical diagnosis and medication 6 
use information in a substantial number of subjects, and the inclusion of the geriatric population 7 
with dementia. Selection bias is mitigated by the wide prescription coverage in this population. 8 
Standardized interRAI HC assessments conducted by trained healthcare personnel facilitates 9 
the provision of valid clinical, social and functional data for research purposes. Various 10 
predictors incorporated in the multivariate regression model, such as living arrangements, 11 
activities of daily living, self-reported health are seldom seen in studies using administrative 12 
claims data; hence, this study provides a unique perspective to the determinants of prescription 13 
of PIMs in older adults with dementia. An additional strength is the application of the updated 14 
2015 Beers criteria. 15 
 16 
Limitations: The prevalence and associations of PIMs with respect to the individual 17 
psychotropic medications were not studied. It was not possible to delineate the subtypes of 18 
dementia. The retrospective analysis may not have been as competent as a prospective research 19 
in outlining the findings of the study. The geriatric risk assessments are conducted in older 20 
individuals living in the community specifically requiring complex care needs, which is 21 
different from surveyed populations of older adults living in the community. Hence, the 22 
findings of this study might not be applicable to community-dwelling older adults in various 23 
countries because of variances in the population, health systems, prescribing guidelines, and 24 
the cost of medications, as all these factors influence prescribing patterns; however, country- 25 
specific guidelines can be developed using this information. The study design is cross-26 
sectional, hence only the associations of prescribing PIMs have been highlighted, and the 27 
causality cannot be established. 28 
 29 
Conclusion: In the present study, we observed that the majority of the individuals diagnosed 30 
with dementia were prescribed PIMs, indicating that the quality of prescribing needs to be 31 
improved.37 Furthermore, important sociodemographic predictors like male gender, European 32 
ethnicity, relatively younger aged individuals,  and clinical predictors like the prescription of 33 
anticholinergic medications, a higher number of medications prescribed, poor self-health, and 34 
12 
 
functionally independent individuals were identified as risk factors for prescribing PIMs in 1 
older adults diagnosed with dementia. Reviewing the modifiable predictors of prescribing 2 
PIMs could significantly reduce the prevalence of inappropriate prescribing in this vulnerable 3 
population.  4 
 5 
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Table 1: List of medications to be avoided in individuals diagnosed with dementia  1 
 2 
*†=(excludes ophthalmic) 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
                 Anticholinergics 
 
Antipsychotics 
 
H2-receptor 
antagonists 
Benzodiazapines 
Chlorpheniramine 
 
Orphenadrine 
 
Diphenhydramine 
(oral) 
 
Benztropine 
 
Amitriptyline 
 
Clomipramine 
 
Doxepin (>6 mg) 
 
Imipramine 
 
Nortriptyline 
 
Paroxetine 
 
Trimipramine 
 
Atropine† 
(excludes 
ophthalmic) 
 
Promethazine 
Homatropine† 
(excludes 
ophthalmic) 
 
Propantheline 
 
Chlorpromazine 
 
Clozapine 
 
Olanzapine 
 
Thioridazine 
 
Trifluoperazine 
 
Oxybutynin 
 
Solifenacin 
 
Tolterodine 
 
Disopyramide 
 
Prochlorperazine 
 
 
 
Haloperidol 
Trifluoperazine 
Fluphenazine 
Chlorpromazine 
Thioridazine 
Aripiprazole  
Quetiapine 
Ziprasidone 
Risperidone 
Clozapine 
Olanzapine 
 
Cimetidine 
 
Ranitidine 
 
Famotidine 
 
Alprazolam 
 
Lorazepam 
 
Oxazepam 
 
Temazepam 
 
Triazolam 
 
Clonazepam 
 
Diazepam 
 
Flurazepam 
 
Meprobamate 
 
Formatted Table
Formatted: Superscript
Formatted: Superscript
Formatted: Pattern: Clear (Background 2)
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 Total PIMs 
 N (%) aOR 95% CI p-value 
Age (years)      
65-74 3,048 (18.4) 1† 1  
75-84 6,776 (40.9) 0.84 (0.69, 1.01) 0.058 
85-94 6,192 (37.4) 0.64 (0.53, 0.77) 0.000 
95+ 552 (3.3) 0.53 (0.38, 0.73) 0.000 
Sex ‡      
Female 9,964 (60.1) 1† 1†  
Male 6,603 (39.9) 1.24 (1.09, 1.41) 0.001 
Ethnicity      
European 14,639 (88.4) 1† 1†  
Māori 957 (5.8) 0.59 (0.47, 0.76) 0.000 
Other 972 (5.9) 0.68 (0.54, 0.87) 0.002 
Marital status      
Married 6,607 (39.9) 1† 1†  
Other 9,961 (60.1) 1.01 (0.80, 1.28) 0.916 
Alcohol      
No 13,225 (79.8) 1† 1†  
Yes 3,343 (20.2) 1.02 (0.88, 1.19) 0.760 
Smoking      
No 15,653 (94.5) 1† 1†  
Yes 915 (5.5) 0.85 (0.66, 1.09) 0.209 
Living arrangements     
Alone 8,019 (48.4) 1† 1†  
Spouse only 5,447 (32.9) 1.14 (0.88, 1.50) 0.327 
Other 1,292 (7.8) 0.79 (0.63, 0.99) 0.050 
With child §  1,810 (10.9) 0.86 (0.71, 1.03) 0.119 
Activities of daily 
living ¶ 
     
Independent 9,985 (60.3) 1† 1†  
Supervision 2,143 (12.9) 0.83 (0.69, 0.99) 0.035 
Limited 1,782 (10.8) 0.94 (0.76, 1.18) 0.642 
Extensive 1,046 (6.3) 0.77 (0.60, 1.00) 0.053 
Maximal 730 (4.4) 0.74 (0.53, 1.02) 0.066 
Dependent+ 880 (5.3) 0.84 (0.60, 1.16) 0.288 
Self-reported health     
Poor 1925 (11.6) 1† 1†  
Excellent 522 (3.2) 0.62 (0.43, 0.89) 0.010 
Good 6,806 (41.1) 0.65 (0.49, 0.85) 0.002 
Fair 5,695 (34.4) 0.80 (0.60, 1.06) 0.124 
Couldn’t  respond 1,620 (9.8) 0.82 (0.59, 1.13) 0.229 
Hospitalisation      
No hospitalisation  
(in last 90 days)  
8,602 (51.9) 1† 1†  
Other 7,966 (48.1) 1.11 (0.97, 1.27) 0.129 
      
Dementia      
19 
 
No 14,378 (86.8) 1† 1†  
Yes 2,190 (13.2) 1.17 (0.99, 1.37) 0.057 
No of meds                                          1.15 (1.14, 1.16) 0.000 
      
    †= Reference value, ‡= 1 missing, §= not spouse / partner, ¶=2 missing. 1 
 2 
